683 Capital Management’s Fate Therapeutics FATE Stock Holding History

683 Capital Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-125,000	Closed	-$11.4M	–	196
2020 Q4	$11.4M	Sell	125,000 -100,000	-44%	-$6.21M	0.54%	46
2020 Q3	$8.99M	Hold	225,000	–	–	0.66%	40
2020 Q2	$7.72M	Hold	225,000	–	–	0.62%	42
2020 Q1	$5M	Hold	225,000	–	–	0.59%	42
2019 Q4	$4.4M	Hold	225,000	–	–	0.5%	48
2019 Q3	$3.49M	Sell	225,000 -75,000	-25%	-$1.44M	0.39%	53
2019 Q2	$6.09M	Sell	300,000 -95,000	-24%	-$1.71M	0.55%	44
2019 Q1	$6.94M	Sell	395,000 -10,000	-2%	-$158K	0.63%	40
2018 Q4	$5.2M	Sell	405,000 -244,800	-38%	-$3.41M	0.31%	55
2018 Q3	$10.6M	Sell	649,800 -94,211	-13%	-$1.11M	0.69%	37
2018 Q2	$8.44M	Sell	744,011 -249,700	-25%	-$2.75M	0.57%	39
2018 Q1	$9.7M	Buy	993,711 +139,911	+16%	+$1.34M	0.86%	35
2017 Q4	$5.22M	Buy	853,800 +175,000	+26%	+$781K	0.44%	62
2017 Q3	$2.69M	Buy	678,800 +90,563	+15%	+$308K	0.28%	71
2017 Q2	$1.91M	Buy	588,237 +118,237	+25%	+$453K	0.28%	65
2017 Q1	$2.14M	Buy	+470,000	New	+$1.72M	0.33%	61

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

683 Capital Management's FATE Position: Q1 2021 in Review

683 Capital Management sold out of Fate Therapeutics (FATE) in Q1 2021, closing a stake of 125,000 shares — an estimated $11.4M sold.

683 Capital Management first reported a position in FATE in Q1 2017 and held it in 16 quarters. The position peaked at $11.4M in Q4 2020. 260 funds tracked by Wall St. Rank hold FATE as of Q1 2021.

683 Capital Management reported no remaining Fate Therapeutics position as of Q1 2021 after selling out during the quarter.
683 Capital Management sold 125,000 Fate Therapeutics shares in Q1 2021, an estimated $11.4M.
683 Capital Management first reported a position in Fate Therapeutics in Q1 2017 and held it in 16 quarters.
683 Capital Management's Fate Therapeutics position peaked at $11.4M in Q4 2020.
260 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2021.

Based on 683 Capital Management's 13F filing for Q1 2021, filed 17 May 2021.